On March 19, the Food and Drug Administration granted traditional approval to pembrolizumab, or Keytruda, marketed by Merck (MRK), with ...
15h
Zacks Investment Research on MSNFDA Accepts RDY & ALVO's Prolia & Xgeva Biosimilar BLA for ReviewDr. Reddy’s Laboratories RDY and partner, Alvotech ALVO, announced the FDA’s acceptance of a regulatory filing, seeking the ...
15h
Zacks Investment Research on MSNJNJ's Nipocalimab Gets FDA's Fast Track Tag for Sjogren's DiseaseJohnson & Johnson JNJ announced that the FDA has granted a Fast Track designation (“FTD’) to its investigational drug, ...
A subcommittee advanced a package dubbed the "Florida Farm Bill." Targets include "any additive" to water "for health-related ...
The Food and Drug Administration (FDA) has expanded the approval of Baqsimi (glucagon) nasal powder to include the treatment of severe hypoglycemia in ...
Dr. Reddy’s Laboratories (RDY) and Alvotech (ALVO) announced that the U.S. FDA has accepted a Biologic License Application submission for AVT03. Read more here.
“The FDA's filing acceptance of Dr. Reddy's proposed denosumab biosimilar marks an important milestone in bringing this biosimilar medication to more patients throughout the U.S.,” said Milan ...
The FDA is reviewing the supplemental NDA for cabozantinib ... The Company is seeking approval for acute treatment of migraine with or without aura.
Tevimbra plus chemotherapy was previously approved to treat advanced gastric and gastroesophageal junction cancers. Credit: Orawan Pattarawimonchai/Shutterstock. The ...
Jurkunas added: “We feel this research warrants additional trials that can help lead towards US Food and Drug Administration (FDA) approval. While we are proud to have been able to bring a new ...
The FDA is reviewing the application for bentracimab for use as a ticagrelor reversal agent in patients with uncontrolled bleeding or in those who require urgent surgery or invasive procedure.
(RTTNews) - Canadian Pacific Kansas City (CPKC) announced that the Toronto Stock Exchange has approved its plan to repurchase up to 37.35 million common shares, representing approximately 4% of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results